NCT07326709ClinicalTrials.gov
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
A Randomized, Placebo-controlled, Double-blind Phase 3 Study to Evaluate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
In brief
The purpose is to assess safety and tolerability of votoplam and to determine whether votoplam slows disease progression in patients with early symptomatic Huntington's disease (HD) compared to the control arm. HTT227 - current compound code (former code is PTC518…
Phase 3770 participants sought117 sites27 countries
Categories
Registered in 1 registry
- ClinicalTrials.govNCT07326709Open this record at ClinicalTrials.govSynced 2 months ago
One study can be registered in several registries. We show it once and link every record we hold.
Trial information is shown as published by the registry, in its original language.
Interested in this study?
Sign in or create an account to register your interest and follow this study.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Present: Registered before enrolment beganFirst posted 2026-01-08; recorded start 2026-03-24
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Present: Participants are randomly assignedAllocation is recorded as randomised
- Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
- Present: Uses blinding (masking)A masking level is recorded in the record
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Present: Sponsor has 1147 other studies in this databaseCounted from the lead sponsor named in the record (Novartis Pharmaceuticals)
- Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
- The record lists 1 condition.
- Lead sponsor type recorded as: industry.
- Intervention regulatory context: investigational, within a phased regulatory pathway.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
A definitive-grade design for a phase 3 study, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation20/20
Participants are randomly allocated between arms
- Blinding20/20
Quadruple-blind
- Control arm13/15
Placebo / sham control arm
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
- Multi-centre8/8
Multi-centre: 41 sites
- Data monitoring committee7/7
A data monitoring committee is in place
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A medium-sized study, international in scope: 770 participants (target), run at 117 sites, across 27 countries.
How this score is built
- Enrolment28/40
770 participants (target)
- Site count19/25
41 sites
- Country count12/15
9 countries
- Planned duration9/10
Planned over about 50 months
- Sponsor scale10/10
Novartis Pharmaceuticals has led 1,104 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
Summary
The purpose is to assess safety and tolerability of votoplam and to determine whether votoplam slows disease progression in patients with early symptomatic Huntington's disease (HD) compared to the control arm. HTT227 - current compound code (former code is PTC518 from PTC Therapeutics), HTT227 is Novartis code under Novartis sponsorship.
Conditions
- Huntington Disease
Eligibility
| Sex | All |
|---|---|
| Ages | 21 Years – 70 Years |
| Healthy volunteers | No |
Eligibility as written in the registry
Eligibility in plain statements
This record's criteria have not been broken into separate statements yet. The registry text above is complete and is the authoritative version.
Study design
| Study type | Interventional |
|---|---|
| Phase | Phase 3 |
| Allocation | Randomised |
| Intervention model | PARALLEL |
| Primary purpose | TREATMENT |
| Masking | QUADRUPLE (4) |
| Enrolment | 770 participants sought |
Sponsor and collaborators
- Novartis Pharmaceuticals Sponsor
Arms and interventions
- VotoplamEXPERIMENTAL
Votoplam (blinded) taken orally, randomized in a 3:2 ratio (Votoplam: Placebo)
- PlaceboPLACEBO_COMPARATOR
Placebo (blinded) taken orally, randomized in a 3:2 ratio (Votoplam: Placebo)
Interventions
- Drug Placebo
Placebo
- Drug Votoplam (blinded)
Votoplam (blinded) active treatment
Outcome measures
Primary outcome
Change from Baseline in cUHDRS score
The Composite Unified Huntingtons Disease Ratings Scale (cUHDRS) is an improved composite measure to assess multi-domain clinical progression in HD. The cUHDRS is a combined weighted score of measures of motor function (TMS), cognition (SDMT and SWRT) and overall functional capacity (TFC): cUHDRS = \[(TFC-10.4)/1.9 - (TMS-29.7)/14.9 + (SDMT-28.4)/11.3 + (SWRT - 66.1)/20.1\] + 10. In conjunction with one another, these measures provide a comprehensive, sensitive and specific tool for monitoring disease progression, with lower scores indicating more severe disease. cUHDRS score range from -8 to 25.
Time frame Baseline, Month 36
Secondary outcome
Change from Baseline in UHDRS-TFC
The UHDRS-Total Functional Capacity (TFC) focuses on the Investigator's assessment of the participant's capacity to perform a range of activities including occupation, finances, self-care, domestic chores and activities of daily living. The responses are derived from interview with the participant and/or companion, if applicable. Scores range from 0 to 13, with higher scores representing better functioning.
Time frame Baseline, Month 36
Secondary outcome
Change from Baseline in UHDRS-IS
The UHDRS-Independence Scale (IS) measures a patient's overall level of functional independence in activities of daily living. It provides a single score ranging from 10 (total dependence/bedbound) to 100 (no special care needed) in intervals of 10, with higher scores indicating better functioning. Scores can also be assigned in increments of 5 for intermediate levels of function.
Time frame Baseline, Month 36
Secondary outcome
The time to decline in TFC score by at least one or IS score by at least 10
The UHDRS-Total Functional Capacity (TFC) focuses on the Investigator's assessment of the participant's capacity to perform a range of activities including occupation, finances, self-care, domestic chores and activities of daily living. The responses are derived from interview with the participant and/or companion, if applicable. Scores range from 0 to 13, with higher scores representing better functioning. The UHDRS-Independence Scale (IS) measures a patient's overall level of functional independence in activities of daily living. It provides a single score ranging from 10 (total dependence/bedbound) to 100 (no special care needed) in intervals of 10, with higher scores indicating better functioning. Scores can also be assigned in increments of 5 for intermediate levels of function.
Time frame Baseline to end of treatment up to 36 months
Secondary outcome
Change from Baseline in UHDRS-TMS
The UHDRS-Total Motor Score (TMS) is the cumulative sum of the individual motor ratings obtained during the administration of the motor assessment portion of the UHDRS. It includes items related to eye movements, speech, limb movements (including hand taps and pronation-supination), dystonia, chorea, and gait/balance. Scores range from 0 to 124, with higher scores indicating greater motor impairment.
Time frame Baseline, Month 36
Secondary outcome
Change from Baseline in SDMT
The Symbol Digit Modality Test (SDMT) is used to assess attention, working memory, psychomotor speed and visual perceptual processing. Participants are presented with a translation key of specific numbers paired with unique abstract symbols. Below the translation key is an array of symbols paired with empty spaces, the participant's task is to match the number for each symbol as quickly as possible in a given time frame. Scores are based on number of correctly paired items and range from 0 to 110, with higher scores representing better performance.
Time frame Baseline, Month 36
Secondary outcome
Change from Baseline in SWRT
The Stroop Word Reading Test (SWRT) is a measure of processing and psychomotor speed. Participants are presented with a list or words (color names) printed in black ink and asked to read aloud as many words as possible within a set timeframe. Scores are based on the number of words read correctly and range from 0 to 60, with higher scores representing better performance.
Time frame Baseline, Month 36
Secondary outcome
Percent change from Baseline in blood mHTT protein
The mutant huntington protein (mHTT) which is detectable both in blood and cerebrospinal fluid (CSF), represents a reliable biomarker for HD due to its direct involvement in disease pathology. Blood mHTT is a direct product of the pathogenic HTT gene mutation and represents a proximal marker of Huntington's disease (HD) biology.
Time frame Baseline to steady state and up to 36 months in blood mHTT protein
Secondary outcome
Change from Baseline in serum NfL
Serum Neurofilament light chain NfL is a component of the neuronal cytoskeleton, released into CSF and blood after neuro-axonal damage, serving as a marker of neurodegeneration and disease progression in HD.
Time frame Baseline, Month 36
Secondary outcome
Incidence and severity of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs) and TEAEs leading to participant withdrawal
Number of participants with AEs and SAEs, including notable findings on physical examination, changes in vital signs, laboratory parameters, ECG, etc.
Time frame Baseline to up to 36 months
Dates
| Start date | March 24, 2026 (actual) |
|---|---|
| Primary completion | April 2, 2030 (estimated) |
| Completion | April 30, 2030 (estimated) |
| First posted | January 8, 2026 (actual) |
| Last updated | September 22, 2026 |
| Results posted | Not stated in the registry record |
| Status last verified | September 2026 |
Actual means the event happened. Estimated means the sponsor expects it. The two mean different things.
Locations
117 sites are recruiting
Argentina
| Facility | City | State or region | Status |
|---|---|---|---|
| Novartis Investigative Site | Buenos Aires | Recruiting | |
| Instituto Argentino de Investigación Neurológica (IADIN) | CABA | Buenos Aires | Recruiting |
| Centro de Investigaciones Metabólicas (CINME) | CABA | Buenos Aires | Recruiting |
| Novartis Investigative Site | Ciudad de | Buenos Aires | Recruiting |
Australia
| Facility | City | State or region | Status |
|---|---|---|---|
| Novartis Investigative Site | Caulfield South | Victoria | Recruiting |
| Novartis Investigative Site | Westmead | New South Wales | Recruiting |
Belgium
| Facility | City | State or region | Status |
|---|---|---|---|
| Novartis Investigative Site | Leuven | Vlaams Brabant | Recruiting |
Bulgaria
| Facility | City | State or region | Status |
|---|---|---|---|
| Novartis Investigative Site | Sofia | Recruiting | |
| Novartis Investigative Site | Sofia | Recruiting |
Canada
| Facility | City | State or region | Status |
|---|---|---|---|
| CUSM Montreal Neurological Institute | Montreal | Quebec | Recruiting |
| Centre de recherche du CHUM | Montreal | Quebec | Recruiting |
| North York General Hospital | North York | Ontario | Recruiting |
China
| Facility | City | State or region | Status |
|---|---|---|---|
| Novartis Investigative Site | Beijing | Recruiting | |
| Novartis Investigative Site | Beijing | Recruiting | |
| The Second Xiangya Hospital of Central South University | Changsha | Hunan | Recruiting |
| West China Hospital of Sichuan Uni | Chengdu | Sichuan | Recruiting |
| Novartis Investigative Site | Fuzhou | Fujian | Recruiting |
| Novartis Investigative Site | Guangzhou | Guangdong | Recruiting |
| Novartis Investigative Site | Guangzhou | Guangdong | Recruiting |
| The Second Affiliated Hosp Of Zhejiang Univ School Of Medicine | Hangzhou | Zhejiang | Recruiting |
| Novartis Investigative Site | Shanghai | Recruiting | |
| Tongji Hos Affiliated Tongji Medical College of Huazhong | Wuhan | Hubei | Recruiting |
Colombia
| Facility | City | State or region | Status |
|---|---|---|---|
| Novartis Investigative Site | Medellín | Recruiting |
Czechia
| Facility | City | State or region | Status |
|---|---|---|---|
| Novartis Investigative Site | Brno | Recruiting | |
| Novartis Investigative Site | Prague | Recruiting |
Denmark
| Facility | City | State or region | Status |
|---|---|---|---|
| Novartis Investigative Site | Copenhagen | Recruiting |
France
| Facility | City | State or region | Status |
|---|---|---|---|
| Novartis Investigative Site | Angers | France | Recruiting |
| Novartis Investigative Site | Marseille | Recruiting | |
| Novartis Investigative Site | Montpellier | Recruiting |
Germany
| Facility | City | State or region | Status |
|---|---|---|---|
| Novartis Investigative Site | Aachen | Recruiting | |
| Novartis Investigative Site | Bochum | Recruiting | |
| Novartis Investigative Site | Münster | Recruiting | |
| Novartis Investigative Site | Tübingen | Recruiting | |
| Novartis Investigative Site | Ulm | Recruiting |
Hungary
| Facility | City | State or region | Status |
|---|---|---|---|
| Novartis Investigative Site | Budapest | Recruiting | |
| Novartis Investigative Site | Szeged | Recruiting |
Israel
| Facility | City | State or region | Status |
|---|---|---|---|
| Tel Aviv Sourasky Med Ctr Ichilov | Tel Aviv | Recruiting |
Italy
| Facility | City | State or region | Status |
|---|---|---|---|
| Novartis Investigative Site | Bologna | BO | Recruiting |
| Novartis Investigative Site | Brescia | BS | Recruiting |
| Novartis Investigative Site | Milan | MI | Recruiting |
| Novartis Investigative Site | Milan | MI | Recruiting |
Japan
| Facility | City | State or region | Status |
|---|---|---|---|
| Novartis Investigative Site | Bunkyo Ku | Tokyo | Recruiting |
| Novartis Investigative Site | Kashihara | Nara | Recruiting |
| Novartis Investigative Site | Sagamihara | Kanagawa | Recruiting |
Netherlands
| Facility | City | State or region | Status |
|---|---|---|---|
| Novartis Investigative Site | Leiden | South Holland | Recruiting |
| Novartis Investigative Site | Maastricht | Limburg | Recruiting |
Poland
| Facility | City | State or region | Status |
|---|---|---|---|
| Novartis Investigative Site | Krakow | POL | Recruiting |
Portugal
| Facility | City | State or region | Status |
|---|---|---|---|
| Novartis Investigative Site | Lisbon | Recruiting | |
| Novartis Investigative Site | Porto | Recruiting |
Romania
| Facility | City | State or region | Status |
|---|---|---|---|
| Novartis Investigative Site | Bucharest | Recruiting |
67 further sites are listed in the registry record.
Study documents
No documents are linked in this registry record.
Changes over time
- September 22, 2026
Site added
35 sites added (117 total)
82117
- August 31, 2026
Site added
22 sites added (82 total)
6082
- August 11, 2026
Site added
9 sites added (60 total)
5160
- July 29, 2026
Site added
10 sites added (51 total)
4151